- Home
- AMSF vs ORIC Comparison
AMSF vs ORIC Comparison
Compare AMSF & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- ORIC
- Stock Information
- Founded
- AMSF 1985
- ORIC 2014
- Country
- AMSF United States
- ORIC United States
- Employees
- AMSF N/A
- ORIC N/A
- Industry
- AMSF Accident &Health Insurance
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- ORIC Health Care
- Exchange
- AMSF Nasdaq
- ORIC Nasdaq
- Market Cap
- AMSF 857.2M
- ORIC 974.1M
- IPO Year
- AMSF 2005
- ORIC 2020
- Fundamental
- Price
- AMSF $44.27
- ORIC $10.78
- Analyst Decision
- AMSF Buy
- ORIC Strong Buy
- Analyst Count
- AMSF 2
- ORIC 10
- Target Price
- AMSF $57.50
- ORIC $17.33
- AVG Volume (30 Days)
- AMSF 75.2K
- ORIC 883.6K
- Earning Date
- AMSF 10-22-2025
- ORIC 11-11-2025
- Dividend Yield
- AMSF 10.30%
- ORIC N/A
- EPS Growth
- AMSF N/A
- ORIC N/A
- EPS
- AMSF 2.63
- ORIC N/A
- Revenue
- AMSF $306,470,000.00
- ORIC N/A
- Revenue This Year
- AMSF $2.98
- ORIC N/A
- Revenue Next Year
- AMSF $5.32
- ORIC N/A
- P/E Ratio
- AMSF $16.83
- ORIC N/A
- Revenue Growth
- AMSF N/A
- ORIC N/A
- 52 Week Low
- AMSF $42.48
- ORIC $3.90
- 52 Week High
- AMSF $60.24
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- AMSF 40.38
- ORIC 57.09
- Support Level
- AMSF $44.65
- ORIC $10.36
- Resistance Level
- AMSF $46.53
- ORIC $11.20
- Average True Range (ATR)
- AMSF 0.90
- ORIC 0.48
- MACD
- AMSF -0.22
- ORIC 0.08
- Stochastic Oscillator
- AMSF 1.91
- ORIC 72.39
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.